Delpor is sketching out late-stage clinical trial plans for its drug-device combination implant DLP-114 (risperidone) in schizophrenia. After presenting topline...
Read more
Delpor announced topline results of its DLP-114 Phase 1b/2a clinical study during which schizophrenia patients received treatment for up...
Read more
Delpor announced that it has initiated and dosed the first subjects in a phase 1 clinical trial of DLP-160,...
Read more
Delpor announced an NIH grant award of $2.5 million for the further advancement of the company’s tizanidine implant product...
Read more
Delpor announced that it has initiated and dosed the first patient in a phase 1b/2a clinical trial of DLP-114,...
Read more
The National Institutes of Health (NIH) has awarded Delpor, Inc. a grant for the development of a Once-Yearly Naltrexone...
Read more
Healthline recently published an article on the importance of implantable drugs, including Delpor’s implant devices. The first half of...
Read more
The NIDDK continues to fund Delpor's efforts to utilize its NANOPOR™ technology in developing a matchstick-size subcutaneous implant device...
Read more
Delpor will be part of the Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing...
Read more
We are delighted to announce that our portfolio company Delpor has been issued another patent by the United States...
Read more